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What is Already Known about this Subject {#bcp13722-sec-0005}
========================================

Although a number of previous studies have evaluated the potential association between *N*‐acetyltransferase type 2 (*NAT2*) polymorphisms and drug‐induced liver injury during anti‐TB treatment (AT‐DILI), the results were inconsistent.

What this Study Adds {#bcp13722-sec-0006}
====================

We conducted a systematic review and performed a meta‐analysis to clarify the role of *NAT2* polymorphism in AT‐DILI. Subgroup analyses were performed by: (i) region of origin, (ii) study type, and (iii) genotyping. We evaluated the risk for specific slow *NAT2* acetylators and susceptibility to AT‐DILI.*NAT2* slow‐acetylator alleles were associated with a higher risk of AT‐DILI, especially in West Asian TB patient populations, but not in European and African populations.Within the slow *NAT2* acetylators, the risk was highest for *NAT2\*6/\*7* and relatively lowest for *NAT2\*5/\*6*.

Introduction {#bcp13722-sec-0007}
============

Tuberculosis (TB) is a major global public health problem. In 2015, there were an estimated 10.4 million new (incident) TB cases worldwide [1](#bcp13722-bib-0001){ref-type="ref"}. The first‐line multidrug combined therapy (<https://pubchem.ncbi.nlm.nih.gov/compound/3767>, <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2765>, <https://pubchem.ncbi.nlm.nih.gov/compound/14052> and <http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=7287>) is known to commonly lead to adverse drug reactions (ADRs) such as hepatotoxicity, gastrointestinal disorders, allergic reactions, arthralgia and neurological disorders [2](#bcp13722-bib-0002){ref-type="ref"}, [3](#bcp13722-bib-0003){ref-type="ref"}, the most common ADR during anti‐TB treatment leading to drug discontinuation in 11% of patients [4](#bcp13722-bib-0004){ref-type="ref"}. Isoniazid is a key drug in anti‐TB therapy but is also the key drug responsible for the occurrence of drug‐induced liver injury during anti‐TB treatment (AT‐DILI). ADRs occur in 5--33% of all patients receiving oral isoniazid treatment at 300 mg once daily [5](#bcp13722-bib-0005){ref-type="ref"}. The metabolic intermediates of isoniazid appear to be the cause of hepatotoxicity [6](#bcp13722-bib-0006){ref-type="ref"}. In the liver, isoniazid is first metabolized into <https://pubchem.ncbi.nlm.nih.gov/compound/71602> via <http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=225#1169> [7](#bcp13722-bib-0007){ref-type="ref"}. Isoniazid hydrazine and acetyl‐hydrazine are two metabolites of isoniazid, which are primarily involved in the mechanism of isoniazid‐induced hepatotoxicity [8](#bcp13722-bib-0008){ref-type="ref"}, [9](#bcp13722-bib-0009){ref-type="ref"}, [10](#bcp13722-bib-0010){ref-type="ref"}. Figure [1](#bcp13722-fig-0001){ref-type="fig"} shows the metabolic pathway of isoniazid.

![Pathways of metabolism of isoniazid](BCP-84-2747-g001){#bcp13722-fig-0001}

The first genetic variation in drug response ever discovered was the *N*‐acetylation of isoniazid [7](#bcp13722-bib-0007){ref-type="ref"}. This variation was later found to be induced mainly by the polymorphisms in *N*‐acetyltransferase 2 coding gene (*NAT2*), and a number of previous studies have assessed the association between *NAT2* gene polymorphism and the AT‐DILI. The results of the studies were inconsistent, mainly due to limited power, Therefore, personalized dosing has not yet been introduced in programmatic anti‐TB treatment. However, considering the potential impact of *NAT2*‐guided dosing on the occurrence of AT‐DILI, we aimed to systematically review and meta‐analyse all published studies designed to assess the presence and strength of the postulated genetic associations between the *NAT2* polymorphisms and susceptibility to AT‐DILI.

Methods {#bcp13722-sec-0008}
=======

Literature search strategy {#bcp13722-sec-0009}
--------------------------

The details of the systematic review and meta‐analysis were registered in the PROSPERO register (registration number CRD42016051722).

Two authors (M.Z. and S.W.) independently searched the PubMed, Medline and EMBASE databases for studies on the association of *NAT2* polymorphisms with risk of DILI up to 31 December 2017 using the search words: ('antituberculosis' or 'anti tuberculosis' or 'tuberculosis') and ('genetic polymorphism\*' or 'polymorphism\*') and ('adverse drug reaction\*' or 'adverse effect\*' or 'adverse event\*' or 'drug reaction\*' or 'drug damage' or 'drug injur\*' or 'drug‐induced'). The search was conducted on human subjects and published in English, having no restrictions on sample size or population. The reference lists from the retrieved documents were also scanned. Through the quick reading of the title and abstract, any clearly irrelevant studies, editorials and review articles were excluded. A flow diagram summarizing the study selection process is shown in Figure [2](#bcp13722-fig-0002){ref-type="fig"}.

![Flowchart for identification of studies in the meta‐analysis](BCP-84-2747-g002){#bcp13722-fig-0002}

*NAT2* activity is divided into three main categories as slow, intermediate and rapid acetylation, with some studies combining intermediate and rapid acetylation. In this review, individuals homozygous for slow *NAT2* acetylator alleles (*NAT2\*5/\*5*, *NAT2\*5/\*6*, *NAT2\*5/\*7*, *NAT2\*6/\*6*, *NAT2\*6/\*7*, *NAT2\*7/\*7*) were classified as slow acetylator phenotype; individuals homozygous for rapid *NAT2* acetylator alleles (*NAT2\*4*, *NAT2\*11A*, *NAT2\*12A*, *NAT2\*12B*, *NAT2\*12C*, *NAT2\*13*) were classified as rapid acetylator phenotype; heterozygous individuals (one rapid and one slow *NAT2* allele) were classified as intermediate acetylator phenotypes [11](#bcp13722-bib-0011){ref-type="ref"}, [12](#bcp13722-bib-0012){ref-type="ref"}, [13](#bcp13722-bib-0013){ref-type="ref"}. The rapid acetylator phenotype and intermediate acetylator phenotypes were classified as non‐slow acetylator phenotype in this review.

Inclusion and exclusion criteria {#bcp13722-sec-0010}
--------------------------------

Eligible studies met the following inclusion criteria: They must (i) have evaluated the association between the *NAT2* genetic polymorphisms and risk of anti‐tuberculosis drug‐induced DILI in humans with either case--control (including nested case--control) or prospective designs, (ii) be original papers containing independent data, (iii) have included sufficient data to estimate odds ratios (ORs) and their 95% confidence intervals (CIs). Studies were excluded if they met the following predetermined criteria: (i) overlapping studies, (ii) review articles, (iii) studies without complete genetic distribution data for the DILI and non‐DILI groups, (iv) Newcastle‐Ottawa quality assessment (NOS) \<4, (v) controls were patients without TB, (vi) not published in English.

Data extraction and assessment of study quality {#bcp13722-sec-0011}
-----------------------------------------------

The data extracted independently by the two reviewers included: name of first author, publication year, country or region of origin, study type, demographic data of age and gender, setting (clinic), stage of treatment, duration of follow‐up, matching factors, treatment regimen, detailed definition of DILI, measurement method for DILI, genotyping method and genotype distribution in cases and controls. The eligibility/exclusion criteria mentioned above were used to assess the quality of the included studies, and study quality was assessed according to Newcastle‐Ottawa quality assessment [14](#bcp13722-bib-0014){ref-type="ref"}. These items included: (i) selection of study subjects, (ii) comparability of cases and controls on the basis of the design or analysis, (iii) assessment exposure or outcome studies with a score ≥4 estimated by the NOS were considered to be of high quality and were retained in the analysis. If any discrepancy occurred, the data were rechecked, and a third author was invited to give a final decision.

Statistical analysis {#bcp13722-sec-0012}
--------------------

The *NAT2* genotypes were analysed based on the genetic model of proposed risk (rapid and intermediate acetylation phenotype *vs*. slow acetylation phenotype) for the *NAT2* polymorphisms. All of the statistical analyses were performed using STATA version 14.2 (Stata, College Station, TX, USA) and SPSS version 16.0 (SPSS, USA). Based on complete distribution data on *NAT2* polymorphism in cases and controls, the pooled ORs and their 95% confidence intervals (CIs) were calculated and displayed as forest plots to assess the strength of association between *NAT2* genetic polymorphisms and susceptibility to AT‐DILI in TB patients. In this analysis, pre‐stated ethnic subgroup analyses were performed to examine differences in the association between *NAT2* genotype distribution and AT‐DILI risk. Subgroup analyses were performed by: (i) region of origin (East Asia, South Asia, Southeast Asia, West Asia, Africa, Europe, South and North America); (ii) study type (case--control study, nested case--control study, cross‐sectional cohort studies, prospective cohort study); and (iii) genotyping (sequencing, HRM, RFLP, Taqman, SNP stream). Random effects or fixed effects models were used depending on the heterogeneity among studies. Heterogeneity was assessed using the standard Q‐statistic test, where *I* ^2^ \> 50% was considered to be evidence of heterogeneity. Among all qualified studies related to *NAT2* gene, we drew up the summary effects again after removing the study with the widest 95% confidence interval (CI). We also conducted a sensitivity analysis to assess the stability of the results by applying the leave‐one‐out method, that is repeating the meta‐analysis, each time omitting one of the studies. Publication bias was assessed using Begg\'s funnel plot and Egger\'s test. A *P*‐value \<0.05 was considered as statistically significant.

Results {#bcp13722-sec-0013}
=======

Identification and characteristics of the included studies {#bcp13722-sec-0014}
----------------------------------------------------------

Using our electronic database searches, we identified 58 articles describing the strength of the postulated genetic associations between the *NAT2* polymorphisms and susceptibility to AT‐DILI. A total of 37 case--control or prospective cohort design studies with 1527 AT‐DILI cases and 7184 controls without AT‐DILI were included in the meta‐analysis. The main characteristics of the 37 studies are shown in Table [1](#bcp13722-tbl-0001){ref-type="table"}. The studies by An *et al*. [15](#bcp13722-bib-0015){ref-type="ref"}, Rana *et al*. [16](#bcp13722-bib-0016){ref-type="ref"} and Rana *et al*. [17](#bcp13722-bib-0017){ref-type="ref"} were excluded due to overlap with their other studies (we therefore selected the later publication to analyse the distribution of the *NAT2* genotype); three studies, by Guaoua *et al*. [18](#bcp13722-bib-0018){ref-type="ref"}, Ng [19](#bcp13722-bib-0019){ref-type="ref"} and Mishra *et al*. [20](#bcp13722-bib-0020){ref-type="ref"}, were excluded as controls were not TB patients but healthy people; the studies by Roy *et al*. [21](#bcp13722-bib-0021){ref-type="ref"} and Cavaco *et al*. [22](#bcp13722-bib-0022){ref-type="ref"} were excluded due to the absence of complete *NAT2* polymorphism distribution data. The study by Ohno *et al*. [23](#bcp13722-bib-0023){ref-type="ref"} was excluded due to the absence of slow acetylators.

###### 

Studies investigating the association between the *NAT2* polymorphisms and AT‐DILI risk

  **Genotype/**                                                     **Year**   **Country**   **Study**                      **NOS**   **Genotyping**   **Sample size**   **Slow acetylators**        
  ----------------------------------------------------------------- ---------- ------------- ------------------------------ --------- ---------------- ----------------- ---------------------- ---- -----
  ***NAT2***                                                                                                                                                                                         
  **Chan** [44](#bcp13722-bib-0044){ref-type="ref"}                 2017       Singapore     Case--control study            6         Sequencing       24                79                     18   17
  **Wattanapokayakit** [45](#bcp13722-bib-0045){ref-type="ref"}     2016       Thailand      Case--control study            5         Sequencing       53                85                     39   21
  **Mushiroda** [46](#bcp13722-bib-0046){ref-type="ref"}            2016       Japan         Case--control study            6         Sequencing       73                293                    13   14
  **Yuliwulandari** [47](#bcp13722-bib-0047){ref-type="ref"}        2016       Indonesia     Case--control study            5         Sequencing       50                191                    32   65
  **Wang** [48](#bcp13722-bib-0048){ref-type="ref"}                 2015       China         Cross‐sectional cohort study   7         Sequencing       70                285                    23   62
  **Ho** [49](#bcp13722-bib-0049){ref-type="ref"}                   2013       China         Nested case--control study     6         Sequencing       19                329                    12   67
  **Lv** [24](#bcp13722-bib-0024){ref-type="ref"}                   2012       China         Nested case--control study     6         RFLP             89                356                    18   74
  **Ben Mahmoud** [50](#bcp13722-bib-0050){ref-type="ref"}          2012       Tunisia       Nested case--control study     6         RFLP             14                52                     11   22
  **Rana** [16](#bcp13722-bib-0016){ref-type="ref"}                 2012       Indian        Case--control study            6         RFLP             50                201                    19   30
  **Leiro‐Fernandez** [51](#bcp13722-bib-0051){ref-type="ref"}      2011       Spain.        Nested case--control study     7         RFLP             50                67                     36   44
  **Sistanizad** [52](#bcp13722-bib-0052){ref-type="ref"}           2011       Iran          Cross‐sectional cohort study   6         RFLP             14                36                     9    11
  **Khalili** [53](#bcp13722-bib-0053){ref-type="ref"}              2011       Iran          Case--control study            6         RFLP             14                36                     9    5
  **Bozok** [54](#bcp13722-bib-0054){ref-type="ref"}                2008       Turkey        Case--control study            6         HRM              30                70                     23   19
  **Higuchi** [30](#bcp13722-bib-0030){ref-type="ref"}              2008       Japan         Nested case--control study     6         RFLP             18                82                     6    4
  **Possuelo** [55](#bcp13722-bib-0055){ref-type="ref"}             2008       Brazil        Prospective cohort study       8         Sequencing       14                240                    9    60
  **Shimizu** [56](#bcp13722-bib-0056){ref-type="ref"}              2005       Japan         Case--control study            5         RFLP             10                32                     4    1
  **Huang** [31](#bcp13722-bib-0031){ref-type="ref"}                2002       China         Nested case--control study     6         RFLP             33                191                    14   39
  ***NAT2, CYP2E1***                                                                                                                                                                                 
  **Rana** [17](#bcp13722-bib-0017){ref-type="ref"}                 2014       India         Prospective cohort study       7         RFLP             55                245                    21   36
  **Chamorro** [57](#bcp13722-bib-0057){ref-type="ref"}             2013       Argentina.    Cross‐sectional cohort study   6         RFLP             47                128                    28   48
  **Gupta** [58](#bcp13722-bib-0058){ref-type="ref"}                2013       India         Nested case--control study     7         RFLP             50                165                    28   63
  **Santos** [59](#bcp13722-bib-0059){ref-type="ref"}               2013       Brazil        Case--control study            6         Sequencing       18                252                    11   75
  **An** [60](#bcp13722-bib-0060){ref-type="ref"}                   2012       China         Case--control study            6         Sequencing       101               107                    40   13
  **Bose** [61](#bcp13722-bib-0061){ref-type="ref"}                 2011       India         Case--control study            7         RFLP             41                177                    29   79
  **Lee** [62](#bcp13722-bib-0062){ref-type="ref"}                  2010       China         Case--control study            7         Taqman           45                95                     21   20
  **Yamada** [63](#bcp13722-bib-0063){ref-type="ref"}               2009       Canada        Case--control study            5         Sequencing       23                147                    14   64
  **Cho** [64](#bcp13722-bib-0064){ref-type="ref"}                  2007       Korean        Case--control study            6         Sequencing       18                114                    7    12
  **Vuilleumier** [65](#bcp13722-bib-0065){ref-type="ref"}          2006       Switzerland   Case--control study            7         RFLP             8                 81                     3    32
  ***NAT2, CYP2E1, GST***                                                                                                                                                                            
  **Chamorro** [66](#bcp13722-bib-0066){ref-type="ref"}             2017       Argentina     Prospective cohort study       6         RFLP             96                249                    64   102
  **Heinrich** [67](#bcp13722-bib-0067){ref-type="ref"}             2016       Brazil        Cross‐sectional cohort study   7         RFLP             20                88                     15   44
  **Singla** [68](#bcp13722-bib-0068){ref-type="ref"}               2014       India         Case--control study            6         RFLP             17                391                    15   213
  **Xiang** [69](#bcp13722-bib-0069){ref-type="ref"}                2014       China         Cross‐sectional cohort study   6         Taqman           71                1614                   28   501
  **Costa** [70](#bcp13722-bib-0070){ref-type="ref"}                2012       Brazil        Prospective cohort study       5         Sequencing       54                75                     22   13
  **Teixeira** [29](#bcp13722-bib-0029){ref-type="ref"}             2011       Brazil        Case--control study            6         Sequencing       26                141                    18   64
  **Sotsuka** [71](#bcp13722-bib-0071){ref-type="ref"}              2011       Japan         Case--control study            6         RFLP             52                92                     8    5
  ***NAT2, CYP2E1, CYP3A4***                                                                                                                                                                         
  **Zaverucha‐do‐Valle** [72](#bcp13722-bib-0072){ref-type="ref"}   2014       Brazil        Retrospective cohort study     7         Sequencing       52                79                     37   36
  ***NAT2, CYP2B6, CYP3A5, ABCB1, UGT2B7, SLCO1B1***                                                                                                                                                 
  **Yimer** [28](#bcp13722-bib-0028){ref-type="ref"}                2011       Ethiopian     Prospective cohort study       5         Sequencing       41                160                    31   107
  ***NAT2, CYP2E1, CYP2C9, CYP2C19, CYP2D6***                                                                                                                                                        
  **Kim** [73](#bcp13722-bib-0073){ref-type="ref"}                  2009       Korean        Case--control study            6         SNP stream       67                159                    21   28

Quantitative synthesis {#bcp13722-sec-0015}
----------------------

Pooling all 37 studies in the meta‐analysis, comparing the slow to the non‐slow *NAT2* acetylators (i.e., intermediate *NAT2* acetylators and fast acetylators), the overall OR for the association with AT‐DILI was 3.15 (95% CI 2.58--3.84, *P* \< 0.005, Figure [3](#bcp13722-fig-0003){ref-type="fig"}) using a random effects model (*I* ^2^ = 51.3%).

![Forest plot of the association of the *NAT2* polymorphism with risk of AT‐DILI (subgroup analyses were performed by region of origin). For each effect measure, the forest plot indicates the pooled treatment effect estimate with its 95% CI, the weight measure and the *I* ^2^ heterogeneity measure among the studies included. CI = confidence interval; OR = odds ratio](BCP-84-2747-g003){#bcp13722-fig-0003}

Subgroup analyses of the *NAT2* polymorphism were performed. First, a subgroup analysis for region of origin was performed (Figure [3](#bcp13722-fig-0003){ref-type="fig"}). In descending effect size, the ORs for slow *NAT2* genotype associated with the risk of AT‐DILI were statistically significant for West Asia 6.42 (95% CI 2.41--17.10), South Asia 3.05 (95% CI 2.20--4.24), South America 3.01 (95% CI 2.29--3.96), and East Asia 2.98 (95% CI 2.03--4.37), but not for North America 2.02 (95% CI 0.82--4.96) (one study only), Africa 2.40 (95% CI 0.78--7.36) and Europe 2.32 (95% CI 0.58--9.24).

Secondly, a subgroup analysis was performed across study designs (Figure [4](#bcp13722-fig-0004){ref-type="fig"}). Of the 37 studies, 19 were case--control studies, seven were nested case--control studies, five were cross‐sectional cohort studies, five were prospective cohort studies, and one was a retrospective cohort study. The subgroups all showed positive effects sizes, ranging from 1.90 (94% CI 1.40--2.58) for cross‐sectional cohort studies to 4.00 (95% CI 3.11--5.14) for case--control studies.

![Forest plot of the association of the *NAT2* polymorphism with risk of AT‐DILI (subgroup analyses were performed by type of study). For each effect measure, the forest plot indicates the pooled treatment effect estimate with its 95% CI, the weight measure and the *I* ^2^ heterogeneity measure among the studies included. CI = confidence interval; OR = odds ratio](BCP-84-2747-g004){#bcp13722-fig-0004}

Subgroup analysis for different methods of genotyping was performed (Figure [5](#bcp13722-fig-0005){ref-type="fig"}). Of the 37 studies, 15 used sequencing, 18 used RFLP, two used Taqman, one used HRM, one used SNP stream. The subgroups all showed positive effects sizes, ranging from 2.06 (95% CI 0.93--4.57) for Taqman to 8.82 (95% CI 3.26--23.89) for HRM (one study only).

![Forest plot of the association of the *NAT2* polymorphism with risk of AT‐DILI (subgroup analyses were performed by method of genotyping). For each effect measure, the forest plot indicates the pooled treatment effect estimate with its 95% CI, the weight measure and the *I* ^2^ heterogeneity measure among the studies included. CI = confidence interval; OR = odds ratio](BCP-84-2747-g005){#bcp13722-fig-0005}

This meta‐analysis also evaluated the risk for specific slow *NAT2* acetylators and susceptibility to AT‐DILI. There were statistically significant associations between *NAT2\*5/\*5*, *NAT2\*5/\*6*, *NAT2\*5/\*7*, *NAT2\*6/\*6*, *NAT2\*6/\*7*, *NAT2\*7/\*7* and the risk of AT‐DILI. Within the slow *NAT2* acetylators, we found a relatively lower risk of AT‐DILI with *NAT2\*5/\*6*. The ORs for *NAT2\*5/\*6* slow *NAT2* acetylators compared with other slow *NAT2* acetylators combined was 0.43 (95% CI 0.27--0.68) (Figure [6](#bcp13722-fig-0006){ref-type="fig"}) using a fixed effects model (*I* ^2^ = 12.8%, *P* = 0.328). In contrast, *NAT2\*6/\*7* was associated with a relative increased risk of AT‐DILI compared to the other slow *NAT2* acetylators combined (OR = 1.68, 95% CI 1.09--2.59) using a fixed effects model (*I* ^2^ = 44.0%, *P* = 0.075) (Figure [7](#bcp13722-fig-0007){ref-type="fig"}).

![Forest plot of the association of the *NAT2\*5/\*6* slow *NAT2* acetylators compared with other slow *NAT2* acetylators combined with risk of AT‐DILI. For each effect measure, the forest plot indicates the pooled treatment effect estimate with its 95% CI, the *I* ^2^ heterogeneity measure among the studies included. CI = confidence interval; OR = odds ratio](BCP-84-2747-g006){#bcp13722-fig-0006}

![Forest plot of the association of the *NAT2\*6/\*7* slow *NAT2* acetylators compared with other slow *NAT2* acetylators combined with risk of AT‐DILI. For each effect measure, the forest plot indicates the pooled treatment effect estimate with its 95% CI, the *I* ^2^ heterogeneity measure among the studies included. CI = confidence interval; OR = odds ratio](BCP-84-2747-g007){#bcp13722-fig-0007}

Sensitivity analyses and publication bias {#bcp13722-sec-0016}
-----------------------------------------

The sensitivity analysis was conducted via sequential analysis after omitting one study at a time to assess the effects of individual studies on the overall meta‐analysis estimate. This analysis shows that the results of the meta‐analysis are statistically robust as the ORs for the overall association of slow acetylators on AT‐DILI remained significant and ranged from 3.03 to 3.25 using random effects models. Heterogeneity was specifically decreased (*I* ^2^ = 41.3%), when the study by Lv *et al*. [24](#bcp13722-bib-0024){ref-type="ref"} was removed.

A funnel plot of these 37 studies suggested a possibility of the preferential publication of positive findings (Figure [8](#bcp13722-fig-0008){ref-type="fig"}). The Egger test provided evidence that there was no small‐study publication bias among the studies included (*P* \< 0.001). The Begg\'s test gave the same result.

![Begg\'s funnel plot to detect publication bias for the *NAT2* polymorphism](BCP-84-2747-g008){#bcp13722-fig-0008}

Discussion {#bcp13722-sec-0017}
==========

This meta‐analysis examined well‐characterized polymorphisms of *NAT2* gene in the relationship to AT‐DILI susceptibility. It determined that *NAT2* slow‐acetylator alleles were associated with a higher risk of AT‐DILI, especially in West Asian TB patient populations. Significant results were also found in South Asian, East Asian and American populations, but not in European and African populations.

The previous meta‐analyses [25](#bcp13722-bib-0025){ref-type="ref"}, [26](#bcp13722-bib-0026){ref-type="ref"}, [27](#bcp13722-bib-0027){ref-type="ref"} did not include data from the African population which has the largest incidence of TB in the world. Compared with the previous meta‐analyses, the present study is much larger, with more than one‐and‐a‐half to two times as many cases. It also adjusts the classification used in the study by Yimer *et al*. [28](#bcp13722-bib-0028){ref-type="ref"}, which categorized Ethiopian patients together with European patients. In contrast to our meta‐analysis, the previous meta‐analysis did not include data from Indonesian populations which has the fifth largest incidence of TB in the world. Therefore, this meta‐analysis is more comprehensive and powerful, especially because it contains Asian countries listed in the top 30 TB "high burden countries" in the 2016 latest global TB report [1](#bcp13722-bib-0001){ref-type="ref"}.

We performed a subgroup analysis for different study designs and methods of genotyping to investigate whether the *NAT2* gene polymorphism was associated differently with AT‐DILI risk when using different designs and genotyping methods. Our results on the role of the polymorphism of *NAT2* in different ethnicities were consistent across study design and genotyping method. Furthermore, we evaluated the risk for specific slow *NAT2* acetylators and susceptibility to AT‐DILI, which previous meta‐analyses never reported.

It came to our attention that although association of *NAT2* slow acetylators with AT‐DILI was not observed for Europeans and Africans, it was observed in the Brazilian study of Teixeira [29](#bcp13722-bib-0029){ref-type="ref"}, which is interesting as the Brazilian population includes contributions from Africans, Europeans and Amerindians in its heritage. Considering the ethnic diversity of the Brazilian population, a more consistent comparison of the results found among these populations would be of importance and could contribute even more to the definition of such association in different populations. At present, there is still a lack of research data on different groups of people in Brazil, and such research should be encouraged in the future.

To our knowledge, this is the first systematic review and meta‐analysis to evaluate the association between specific slow *NAT2* acetylators and the susceptibility to AT‐DILI. Previous studies only showed that the *NAT2\*6* allele significantly predicts predisposition to AT‐DILI in Taiwanese, Japanese and Chinese individuals [24](#bcp13722-bib-0024){ref-type="ref"}, [30](#bcp13722-bib-0030){ref-type="ref"}, [31](#bcp13722-bib-0031){ref-type="ref"}. Of the 37 studies included in our meta‐analysis, nine investigated the association between slow *NAT2* acetylators and susceptibility to AT‐DILI and when combined, showed a relatively higher risk of AT‐DILI with *NAT2\*6/\*7*, which is in accordance with previous studies in Taiwanese, Japanese and Chinese populations.

The World Health Organization reported that over 95% of TB deaths occur in low‐ and middle‐income countries. Six countries account for 60% of the total, with India leading the count, followed by Indonesia, China, Nigeria, Pakistan and South Africa [1](#bcp13722-bib-0001){ref-type="ref"}. In Figure [3](#bcp13722-fig-0003){ref-type="fig"}, we can see that two‐thirds of included studies were conducted in East Asian, South Asian and Southeast Asian populations, from India, Indonesia, China, Taiwan, Iran, Japan and Korea. The pharmacokinetic profiles of INH and its metabolites differ significantly between individuals. Patients can be categorized according to their number of functional *NAT2* alleles into slow, intermediate and fast acetylator phenotypes. Therefore, it should be feasible and would be useful to help guide programmatic TB drug therapy through pharmacogenomics, to reduce the occurrence of ADRs in individual patients.

To provide a rational dosing design to balance the inherent trade‐off between treatment efficacy and toxicity in INH‐based chemotherapy, it should be considered that there are several polymorphisms in *NAT2* leading to altered catalytic activities for INH acetylation [32](#bcp13722-bib-0032){ref-type="ref"}, [33](#bcp13722-bib-0033){ref-type="ref"}, [34](#bcp13722-bib-0034){ref-type="ref"}, [35](#bcp13722-bib-0035){ref-type="ref"}. Some authors suggested that an adaptation of administered INH dosages according to patient acetylator status may benefit patients [36](#bcp13722-bib-0036){ref-type="ref"}, [37](#bcp13722-bib-0037){ref-type="ref"}, [38](#bcp13722-bib-0038){ref-type="ref"}. In one clinical trial an INH QD dose of 5 mg kg^−1^ of body weight was modified to doses of 2.5 mg kg^−1^ for slow acetylators, 5 mg kg^−1^ for intermediate acetylators and 7.5 mg kg^−1^ for fast acetylators, resulting in reduced adverse effects in fast acetylators while maintaining overall treatment efficacy in all acetylator phenotypes [37](#bcp13722-bib-0037){ref-type="ref"}.

In the past five years, personalized dosing therapy based on drug metabolizing enzymes and transporter genomes has become one of the focuses of personalized medicine. If the association between the genetic polymorphisms and risk of AT‐DILI is determined, maybe a personalized clinical drug--dosage model can be developed for the treatment of tuberculosis taking into account other well‐known factors that influence drug exposure [39](#bcp13722-bib-0039){ref-type="ref"}, [40](#bcp13722-bib-0040){ref-type="ref"}. The personalized clinical drug--dosage model is especially important for the population of South and East Asia with high incidence of AT‐DILI. It could effectively reduce the incidence of ADRs in the treatment of tuberculosis, especially for the treatment interruption caused by AT‐DILI. For the high‐burden TB countries, reducing the incidence of ADRs may be cost‐effective because the cost of treating AT‐DILI is often higher than the treatment of TB [1](#bcp13722-bib-0001){ref-type="ref"}. The WHO "End TB Strategy", approved by the World Health Assembly in 2014, calls for a 90% reduction in TB deaths and an 80% reduction in the TB incidence rate by 2030, compared with 2015 [41](#bcp13722-bib-0041){ref-type="ref"}. This clinical model of tuberculosis drug therapy could play a role in the realization of this goal.

Although we included a large number of studies with a considerable overall sample size and performed subgroup analyses to explore differences in effects of the *NAT2* polymorphisms on AT‐DILI risk, several potential limitations should be taken into consideration when interpreting our results. Firstly, the *NAT2* polymorphism has a higher minor allele frequency in different populations, so the lack of information about polymorphism distributions in the target populations does not allow us to estimate the attributable fraction of *NAT2* polymorphisms on AT‐DILI occurrence. Secondly, the lack of information on other potential causative/protective factors, in particular age, sex, dietary habits, nutrition status, body mass index (BMI), drinking and smoking habits, were available for only a limited number of the studies and, as such, we were not able to adjust effect sizes. Thirdly, not all studies provided information on the definitions applied for AT‐DILI and hepatotoxicity. Lastly, only some studies provided information on synergism of the TB drugs used and the Hardy--Weinberg equilibrium test, which may have impacted the effect size, and simultaneously hindered an adequate exploration of a potential source of heterogeneity. Despite these limitations, our review and meta‐analysis provides important new information that is statistically robust in sensitivity analyses and has yielded relevant and reliable results.

Conclusion {#bcp13722-sec-0018}
==========

In summary, this meta‐analysis not only demonstrated that the *NAT2* slow acetylation phenotype was significantly associated with increased risk of AT‐DILI depending on the population studied, it also suggests that there is variation within the slow *NAT2* acetylator group: the risk was highest for *NAT2\*6/\*7* and relatively lowest for *NAT2\*5/\*6*. In March 2016, the United States Clinical Pharmacogenetics Implementation Consortium updated 33 pharmacogenomic drug application guidelines, 25 of which relate to drug metabolism and transport. *NAT2* has not yet been included in these guidelines but, based on our results, may have a place in future updates. Considering the complex mechanisms involved in the development of AT‐DILI, and limitations of the available observational studies on the impact of *NAT2* polymorphisms, we recommend a randomized controlled trial be designed with adequate sample size to assess the true effect of *NAT2*. Also evaluating gene‐to‐gene interactions (between human genetic polymorphisms and risk of AT‐DILI, such as *CYP2E1*, *GST*, *CYP3A4*, *CYP2C19*) should be encouraged. Additional evidence from such well‐designed trials would support guideline development and would aid development of a clinical tool for INH dosage adjustment based on genetic and clinical risk factors, in order to reduce hepatoxicity and improve TB treatment outcomes.

Nomenclature of targets and ligands {#bcp13722-sec-0019}
-----------------------------------

Key protein targets and ligands in this article are hyperlinked to corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [42](#bcp13722-bib-0042){ref-type="ref"}, and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [43](#bcp13722-bib-0043){ref-type="ref"}.
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